CoChat
Sign Up
Cited by 12Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapyAdvanced Breast Cancer Therapies

The DOI matches its Crossref record.

LBA85 Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE

Open access
Chi, K.N.N., Castro, E., Attard, G., Smith, M.R., Sandhu, S.K., Efstathiou, E., Roubaud, G., Small, E.J.J., Gomes, A.J.P.D.S., Rathkopf, D., Saad, M., Gurney, H.P., Jung, W., Mason, G.E., Dibaj, S., Wu, D., Diorio, B., Lopez-Gitlitz, A., Kim, W., Olmos, D.·2023·Annals of Oncology
DOI 10.1016/j.annonc.2023.10.087
Open this paper in CoChat — free accountOpen PDF

Overview

Integrity signals

Registry

Crossref · 10.1016/j.annonc.2023.10.087

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Patients with mCRPC who developed resistance on a prior ARPI were not represented in PROpel, MAGNITUDE, or TALAPRO-2, so the benefit of these combinations in these patients is not known.

    “Of note, patients with mCRPC who developed resistance on a prior ARPI were not represented in PROpel, MAGNITUDE, or TALAPRO-2, so the benefit of these combinations in these patients is not known [28, 60, 63].”

    From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [63]

  • Final OS analysis of patients with BRCAm mCRPC demonstrated improved OS for patients receiving niraparib plus abiraterone after pre-specified adjustment for imbalances in baseline characteristics (HR 0.66; 95% CI 0.46-0.95; p = 0.02).

    “Final OS analysis of patients with BRCAm mCRPC demonstrated improved OS for patients receiving niraparib plus abiraterone after pre-specified adjustment for imbalances in baseline characteristics (HR 0.66; 95% CI 0.46–0.95; p = 0.02) [63].”

    From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [63]

Citations

Cites

Still being checked.

Cited by

Sorted by citations

Related

Metadata

Authors
Chi, K. N. N., Castro, E., Attard, G., Smith, M. R., Sandhu, S. K., Efstathiou, E., Roubaud, G., Small, E. J. J., Gomes, A. J. P. D. S., Rathkopf, D., Saad, M., Gurney, H. P., Jung, W., Mason, G. E., Dibaj, S., Wu, D., Diorio, B., Lopez-Gitlitz, A., Kim, W., & Olmos, D.
Affiliations
  • University of British Columbia (CA)
  • Hospital Universitario 12 De Octubre (ES)
  • University College London (GB)
  • Harvard University (US)
  • Peter MacCallum Cancer Centre (AU)
  • Houston Methodist (US)
  • Institut Bergonié (FR)
  • University of California San Francisco Medical Center (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • University Malaya Medical Centre (MY)
  • Macquarie University (AU)
  • Keimyung University Daegu Dongsan Hospital (KR)
  • Janssen Research & Development (United States) (US)
ORCID
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2023-10
Volume
34
Pages
S1326
ISSN
0923-7534 (ISSN-L)
DOI
10.1016/j.annonc.2023.10.087
OpenAlex
W4387809547
Cited by
12
References
0
Citations by year
2025: 4 · 2024: 6 · 2023: 2
Type
conference abstract
Language
en
Open access
Licence
Locations
Annals of Oncology (publishedVersion)
Funders
  • Pfizer
  • AstraZeneca
  • Sanofi
  • National Evidence-based Healthcare Collaborating Agency
  • Astellas Pharma
  • Janssen Research and Development
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords
niraparib, abiraterone, prednisone, metastatic castration-resistant prostate cancer, BRCA mutations, PARP inhibitors, first-line therapy, overall survival, radiographic progression-free survival, multivariate analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review